ESPR
Esperion Therapeutics, Inc. · Healthcare
Insiders sold $240K net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Jun 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$695K
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Jul 13, 2026
Looker Benjamin
Esperion Therapeutics, Inc. (ESPR) has 32 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 13, 2026.
Inside the rolling window, 3 insiders at Esperion Therapeutics, Inc. reported no open-market purchases and 14 open-market sales totaling $695K. The most active filer is Chief Legal Officer Looker Benjamin with 6 filings. Insiders have net sold $348K over the trailing 6 months. The most recent open-market filing is a sale of 11,824 shares by Chief Legal Officer Looker Benjamin, dated Jun 17, 2026, worth $37K.
- Industry:Biotechnology
- CEO:Sheldon L. Koenig
- Employees:294
- HQ:Ann Arbor, MI, US
- IPO:2013-06-26
| Source | |||||||
|---|---|---|---|---|---|---|---|
Looker BenjaminFirst in 3 months | Chief Legal Officer | Sale | 11,824 | $37K | Jun 18 | +1.0% | SEC ↗ |
Halladay BenjaminFirst in 3 months | Chief Financial Officer | Sale | 10,773 | $34K | Jun 18 | +1.0% | SEC ↗ |
Koenig Sheldon L.First in 3 months | President and CEO | Sale | 53,588 | $169K | Jun 18 | +1.0% | SEC ↗ |
Koenig Sheldon L.First in 3 months | President and CEO | Sale | 25,578 | $70K | Mar 18 | +26.9% | SEC ↗ |
Halladay BenjaminFirst in 3 months | Chief Financial Officer | Sale | 6,424 | $17K | Mar 18 | +26.9% | SEC ↗ |
| Chief Legal Officer | Sale | 5,708 | $15K | Mar 18 | +26.9% | SEC ↗ | |
| General Counsel | Sale | 1,689 | $5K | Jan 21 | +6.7% | SEC ↗ | |
Koenig Sheldon L.First in 3 months | President and CEO | Sale | 48,244 | $177K | Dec 18 | -16.3% | SEC ↗ |
| General Counsel | Sale | 6,517 | $24K | Dec 18 | -16.3% | SEC ↗ | |
Halladay BenjaminFirst in 3 months | Chief Financial Officer | Sale | 7,337 | $27K | Dec 18 | -16.3% | SEC ↗ |
| General Counsel | Sale | 1,248 | $3K | Oct 20 | — | SEC ↗ | |
Koenig Sheldon L.First filing | President and CEO | Sale | 28,427 | $79K | Sep 18 | — | SEC ↗ |
Halladay BenjaminFirst filing | Chief Financial Officer | Sale | 7,046 | $20K | Sep 18 | — | SEC ↗ |
Looker BenjaminFirst filing | General Counsel | Sale | 6,267 | $18K | Sep 18 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does ESPR have?
Esperion Therapeutics, Inc. (ESPR) has 32 SEC Form 4 filings (32 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Jul 13, 2026.
When was the most recent SEC Form 4 filing for ESPR?
The most recent Form 4 filing for ESPR on Tracefour is dated Jul 13, 2026.
Who is the most active insider at ESPR?
The most active SEC Form 4 filer at ESPR in the rolling window is Chief Legal Officer Looker Benjamin, with 6 filings.
What is the net insider flow at ESPR over the last 6 months?
Over the trailing 180 days, insiders at ESPR have net sold $348K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ESPR in the current window?
Inside the rolling window, insiders at ESPR bought $0 and sold $695K based on SEC Form 4 filings.
Can I get alerts for ESPR insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Esperion Therapeutics, Inc. (ESPR). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Esperion Therapeutics, Inc. is in the Healthcare sector.